Best Infectious Diseases Companies in Australia
The 34 best Infectious Diseases companies in Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: SpeeDx.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Australia
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SpeeDx Provider of qPCR-based molecular diagnostics platform | $78M | 43 mo ago | Series C | 113 | Alison Todd Co-Founder | WordPressMySQLPHP+41 | — | — |
| 2 | Recce Developer of antibiotics for drug-resistant bacteria and cancer treatments | $41M | 16 mo ago | Public | — | James Graham CEO | WordPressMySQLPHP+26 | 8 patents Antimicrobial polymers for treating viral and bacterial infections | — |
| 3 | Hatchtech Developer of proprietary head lice drugs | $31M | 155 mo ago | Series B | 4 | — | — | — | — |
| 4 | Topelia Developer of antiviral triple therapy for coronavirus infection | $25M | 60 mo ago | Series A | — | David Fox CEO | — | — | — |
| 5 | GPN Vaccines Developer of a vaccine against Streptococcus pneumonia | $18M | 10 mo ago | Series B | 24 | — | WordPressMySQLPHP+13 | 21 patents Streptococcal vaccine formulations targeting bacterial protein antigens for immunization | — |
| 6 | BioDiem Developing and commercializing vaccine technology and infectious disease therapies. | $11M | 135 mo ago | Funding Raised | 5 | — | — | 53 patents Novel nitrostyrene-based antifungal agents for Scedosporium infections. | — |
| 7 | BiomeBank Developer of microbial therapies to treat diseases | $11M | 46 mo ago | Series B | 22 | Sam Costello Co-Founder & CEO | Cart FunctionalityWordPressApple iCloud Mail+29 | — | — |
| 8 | Genetic Signatures Molecular diagnostic reagents and kits for pathogen detection | $11M | 121 mo ago | Public | — | — | WordPressApple iCloud MailMySQL+26 | 165 patents Isothermal nucleic acid amplification and microbial DNA preparation for rapid molecular diagnostics | — |
| 9 | Island Pharmaceuticals Developer of antiviral therapeutics for infectious diseases | $7M | 8 mo ago | Public | — | David Foster Chief Executive Officer and Managing Director | ZURB FoundationMicrosoft ASP.NETCloudflare+13 | 2 patents Antiviral drug formulations targeting SARS‑CoV‑2 and polymerase inhibition therapies | — |
| 10 | Ellume Developer of a diagnostic device that uses quantum dot nanoparticles to provide real-time patient testing | $5M | 68 mo ago | Series A | 135 | Sean Parsons Founder & MD | WordPressMySQLPHP+16 | 52 patents Fluorescent lateral‑flow diagnostic devices and sample collection for rapid pathogen testing | — |
| 11 | Implicit Bioscience Develops therapeutics for infectious diseases | $768K | 73 mo ago | Seed | 11 | Garry Redlich CEO & MD | — | 41 patents Novel peptide/antibody therapeutics for heart, muscle, and neurodegenerative diseases | — |
| 12 | Zip Diagnostics Developer of molecular diagnostic tests and instruments for infectious diseases | $750K | 66 mo ago | Funding Raised | — | Jack Richards Co-Founder | Wix eCommerceCart FunctionalityWix+20 | 7 patents Rapid lateral‑flow immunoassay devices for point‑of‑care biological and environmental testing | — |
| 13 | Gamma Vaccines Australian Biotech developing broad-spectrum, intranasal vaccines against human and avian influenza virus | $552K | 202 mo ago | Seed | — | Tim Hirst Founder & Executive Director | — | 25 patents Gamma-irradiated viral vaccine platforms for combination influenza and other immunogens | — |
| 14 | Aviragen Therapeutics Anti-infective drugs for respiratory diseases | $423K | 126 mo ago | Public | 115 | Peter Cook CEO | — | — | — |
Top 12 Infectious Diseases companies in Australia
#1
Series B · Canberra, Australian Capital Territory · founded 2017 · 24 employees$18Mraised▾
Developer of a vaccine against Streptococcus pneumonia. The vaccine Gamma-PN is a whole-cell vaccine that is capable of inducing broad-spectrum T- and B-cell immunity. This is developed by using a gamma-irradiation process that inactivates and kills the vaccine strain but surface protein antigens are conserved and maintained during vaccine production that provides immunity.
- Dec 2025Series B$3.5M
- Jun 2024Series B$18M
#2
Public · Camberwell, Victoria · founded 2016$7.5Mraised▾
Developer of antiviral therapeutics for infectious diseases. The lead drug candidate ISLA-101 is repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases. It prevents nuclear entry of the viral protein that prevents propagation of the viral infection.
- Feb 2026Post IPO$6.3M
- Mar 2024Post IPO$1.2M
#3
Public · Sydney, New South Wales · founded 2007$40.8Mraised▾
Developer of antibiotics for drug-resistant bacteria and cancer treatments. The company's pipeline includes RECCE 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE 435 (R435) as an orally administered therapy for bacterial infections; and RECCE 529 (R529) for viral infections.
- Jun 2025Post IPO$4.8M
- Apr 2025Post IPO$10.1M
- Sep 2020Post IPO$20.1M
- Oct 2019Post IPO$4.6M
#4
Series C · Sydney, New South Wales · founded 2009 · 113 employees$78Mraised▾
Provider of qPCR-based molecular diagnostics platform. The company's products include multiplexed assays for HSV-1 and -2, VZV, and Syphilis, and detecting the presence of Mycoplasma genitalium as well as antibiotic resistance. The products are based on plexZyme technology where primers amplify target nucleic acid sequences and produce an amplicon.
- Feb 2023Series C$26M
- May 2021Grant (prize money)—
- Sep 2020Grant (prize money)—
- Feb 2020Series B$15M
#5
Series A · Sydney, New South Wales · founded 2021$25Mraised▾
Developer of antiviral triple therapy intended to commercialize the triple therapy cure for peptic ulcers. The company's product offers antiviral combination therapy that provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19, helping patients to treat and prevent dangerous diseases.
- Oct 2021Series A$25M
#6
Series B · Thebarton, South Australia · founded 2018 · 22 employees$10.7Mraised▾
Developer of microbial therapies to treat diseases. It offerz BiomeBoost, a drug that contains microbes for the treatment of recurrent or refractory Clostridioides difficile infection. The company has a platform that combines microbiology, machine learning, and bioinformatics for the discovery of microbial biomarkers, leads, and targets. It also collects stools for the research and development of microbial therapies.
- Dec 2022Series B$10.7M
#7
Series B · Camberwell, Victoria · founded 2001 · 4 employees$31.4Mraised▾
Hatchtech, a specialty pharmaceutical company developing Xeglyze Lotion (previously DeOvoLotion ), a proprietary next generation head lice treatment. Xeglyze is a topical lotion containing an inhibitor of metalloproteinases known to impede a number of physiological processes involved in all stages of the louse lifecycle from egg to adult. Xeglyze Lotion recently completed two phase III clinical studies conducted under a Special Protocol Agreement with the U.S. Food and Drug Administration (FDA).
- Oct 2013Series B$11.9M
- Apr 2012Series B$8.1M
- Oct 2010Series A$6.3M
- Nov 2008Series A$2.5M
#8
Funding Raised · South Melbourne, Victoria · founded 2001 · 5 employees$11.2Mraised▾
BioDiem is focused on developing and commercializing vaccines and infectious disease therapies. The company has a Live Attenuated Influenza Virus (LAIV) vaccine technology which is used for the production of seasonal and pandemic influenza vaccines. This technology is licensed currently to two commercial partners, in India and China, and is licensed to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to increase vaccine supply. The company subsidiary, Opal Biosciences is developing BDM-I, a novel antimicrobial compound being developed against a range of pathogenic micro-organisms such as MRSA.
- Jul 2015Grant (prize money)$241.6K
- Sep 2012Post IPO$2.6M
- Oct 2007Post IPO$6.3M
- 2006Grant (prize money)$2.1M
#9
Series A · Brisbane, Queensland · founded 2010 · 135 employees$5Mraised▾
Ellume has is a developer of a diagnostic device that uses quantum dot fluorescent nanoparticles as biological detectors. It provides real-time patient testing with features such as encrypted patient data and images, connectivity to access user information, and claims to provides results in approximately seven minutes. The company has developed tests for Influenza A+B, Respiratory Syncytial Virus, Group A Streptococcus, and aims to create tests for more respiratory viruses and bacterial infections.
- Feb 2021Grant (prize money)$230M
- Jun 2019Series A$5M
#10
Public · Darlinghurst, New South Wales · founded 2001$10.7Mraised▾
Genetic Signatures develops and markets diagnostic reagents and kits for pathogen detection. Its proprietary 3Base technology uses the bisulfite method to enable pathogen detection by differentiating between methylated and unmethylated cytosine residues. Its flagship range of products EaasyScreen allows for the easy multiplexing of tests and is applicable for both DNA and RNA.
- Sep 2016Post IPO$10.7M
#11
Seed · Brisbane, Queensland · founded 2004 · 11 employees$767.8Kraised▾
Implicit Biosciences develops therapeutics for infectious diseases. Its dipeptide candidates aim to treat infectious diseases by modulating immune response to pathogens. Its lead candidate is the small molecule dipeptide oglufanide disodium for diseases such as leishmaniasis and dengue fever, hospital acquired infections and biothreats.
- Sep 2020Seed$65.6K
- Sep 2019Seed$367.2K
- Sep 2017Seed$125K
- Sep 2016Seed$210.1K
#12
Funding Raised · Collingwood, Victoria · founded 2019$750Kraised▾
Developer of molecular diagnostic tests and instruments for infectious diseases. The company is developing a sensitivity molecular test system for SARS-CoV-2 and sexually transmitted diseases.
- Apr 2021Grant (prize money)$750K
Funding & investor landscape
Notable founders
How research on Diagnostics is moving in Australia
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,143 Australia-affiliated papers.
- University College London133
- Monash University78
- UNSW Sydney76
- The University of Queensland69
- Burnet Institute59
- Liquid biopsy3→24
- Point-of-care testing10→30
- Point of care3→19
- Computational biology1→12
- Cancer1→6
- Liquid biopsy11→88
- Biopsy1→26
- Biomarker3→27
- Cancer4→26
- Circulating tumor cell2→21
- Liquid biopsy11→26
- Test (biology)6→15
- Biopsy1→10
- Computational biology1→8
- Loop-mediated isothermal amplification1→7
Where diagnostics is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.